Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies.

Autor: Ansell SM; Division of Hematology, Mayo Clinic, Rochester, Minnesota. ansell.stephen@mayo.edu., Maris MB; Colorado Blood Cancer Institute and Sarah Cannon Research Institute, Denver, Colorado., Lesokhin AM; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Chen RW; Department of Hematology and Hematopoietic Transplantation, City of Hope Medical Center, Duarte, California., Flinn IW; Sarah Cannon Research Institute, Nashville, Tennessee.; Tennessee Oncology, Nashville, Tennessee., Sawas A; Center for Lymphoid Malignancies, Columbia University Medical Center, College of Physicians and Surgeons, New York, New York., Minden MD; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada., Villa D; Division of Medical Oncology and Centre for Lymphoid Cancer, BC Cancer, Vancouver, British Columbia, Canada., Percival MM; Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington.; Division of Hematology, University of Washington, Seattle, Washington., Advani AS; Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio., Foran JM; Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, Florida., Horwitz SM; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Mei MG; Department of Hematology and Hematopoietic Transplantation, City of Hope Medical Center, Duarte, California., Zain J; Department of Hematology and Hematopoietic Transplantation, City of Hope Medical Center, Duarte, California., Savage KJ; Division of Medical Oncology and Centre for Lymphoid Cancer, BC Cancer, Vancouver, British Columbia, Canada., Querfeld C; Department of Hematology and Hematopoietic Transplantation, City of Hope Medical Center, Duarte, California., Akilov OE; Cutaneous Lymphoma Program, Department of Dermatology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania., Johnson LDS; Trillium Therapeutics Inc., Mississauga, Ontario, Canada., Catalano T; Trillium Therapeutics Inc., Mississauga, Ontario, Canada., Petrova PS; Trillium Therapeutics Inc., Mississauga, Ontario, Canada., Uger RA; Trillium Therapeutics Inc., Mississauga, Ontario, Canada., Sievers EL; Trillium Therapeutics Inc., Mississauga, Ontario, Canada., Milea A; Trillium Therapeutics Inc., Mississauga, Ontario, Canada., Roberge K; Trillium Therapeutics Inc., Mississauga, Ontario, Canada., Shou Y; Trillium Therapeutics Inc., Mississauga, Ontario, Canada., O'Connor OA; University of Virginia Cancer Center, Charlottesville, Virginia.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2021 Apr 15; Vol. 27 (8), pp. 2190-2199. Date of Electronic Publication: 2021 Jan 15.

TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding.

Autor: Petrova PS; Trillium Therapeutics Inc., Mississauga, Ontario, Canada., Viller NN; Trillium Therapeutics Inc., Mississauga, Ontario, Canada., Wong M; Trillium Therapeutics Inc., Mississauga, Ontario, Canada., Pang X; Trillium Therapeutics Inc., Mississauga, Ontario, Canada., Lin GH; Trillium Therapeutics Inc., Mississauga, Ontario, Canada., Dodge K; Trillium Therapeutics Inc., Mississauga, Ontario, Canada., Chai V; Trillium Therapeutics Inc., Mississauga, Ontario, Canada., Chen H; Trillium Therapeutics Inc., Mississauga, Ontario, Canada., Lee V; Trillium Therapeutics Inc., Mississauga, Ontario, Canada., House V; Trillium Therapeutics Inc., Mississauga, Ontario, Canada., Vigo NT; Trillium Therapeutics Inc., Mississauga, Ontario, Canada., Jin D; Trillium Therapeutics Inc., Mississauga, Ontario, Canada., Mutukura T; Trillium Therapeutics Inc., Mississauga, Ontario, Canada., Charbonneau M; Trillium Therapeutics Inc., Mississauga, Ontario, Canada., Truong T; Trillium Therapeutics Inc., Mississauga, Ontario, Canada., Viau S; Trillium Therapeutics Inc., Mississauga, Ontario, Canada., Johnson LD; Trillium Therapeutics Inc., Mississauga, Ontario, Canada., Linderoth E; Trillium Therapeutics Inc., Mississauga, Ontario, Canada., Sievers EL; Trillium Therapeutics Inc., Mississauga, Ontario, Canada., Maleki Vareki S; London Regional Cancer Program, London Health Sciences Centre, Lawson Heath Research Institute, London, Ontario, Canada.; Department of Oncology, University of Western Ontario, London, Ontario, Canada., Figueredo R; London Regional Cancer Program, London Health Sciences Centre, Lawson Heath Research Institute, London, Ontario, Canada.; Department of Oncology, University of Western Ontario, London, Ontario, Canada., Pampillo M; London Regional Cancer Program, London Health Sciences Centre, Lawson Heath Research Institute, London, Ontario, Canada., Koropatnick J; London Regional Cancer Program, London Health Sciences Centre, Lawson Heath Research Institute, London, Ontario, Canada.; Department of Oncology, University of Western Ontario, London, Ontario, Canada., Trudel S; Princess Margaret Cancer Center, University Health Network (UHN), Toronto, Ontario, Canada., Mbong N; Princess Margaret Cancer Center, University Health Network (UHN), Toronto, Ontario, Canada., Jin L; Princess Margaret Cancer Center, University Health Network (UHN), Toronto, Ontario, Canada., Wang JC; Princess Margaret Cancer Center, University Health Network (UHN), Toronto, Ontario, Canada.; Division of Medical Oncology and Hematology, Department of Medicine, UHN, and Department of Medicine, University of Toronto, Toronto, Ontario, Canada., Uger RA; Trillium Therapeutics Inc., Mississauga, Ontario, Canada. bob@trilliumtherapeutics.com.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2017 Feb 15; Vol. 23 (4), pp. 1068-1079. Date of Electronic Publication: 2016 Nov 17.